Skip to main content

TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker.

Publication ,  Conference
Mayer, EL; Vaz-Luis, I; Richardson, AL; Perou, CM; Tung, NM; Abramson, VG; Anders, CK; Forero-Torres, A; Marcom, PK; Miller, K; Puhalla, S ...
Published in: Journal of Clinical Oncology
May 20, 2014

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2014

Volume

32

Issue

15_suppl

Start / End Page

TPS1145 / TPS1145

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mayer, E. L., Vaz-Luis, I., Richardson, A. L., Perou, C. M., Tung, N. M., Abramson, V. G., … Winer, E. P. (2014). TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker. In Journal of Clinical Oncology (Vol. 32, pp. TPS1145–TPS1145). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.tps1145
Mayer, Erica L., Ines Vaz-Luis, Andrea L. Richardson, Charles M. Perou, Nadine M. Tung, Vandana Gupta Abramson, Carey K. Anders, et al. “TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker.” In Journal of Clinical Oncology, 32:TPS1145–TPS1145. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps1145.
Mayer EL, Vaz-Luis I, Richardson AL, Perou CM, Tung NM, Abramson VG, et al. TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. TPS1145–TPS1145.
Mayer, Erica L., et al. “TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker.Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. TPS1145–TPS1145. Crossref, doi:10.1200/jco.2014.32.15_suppl.tps1145.
Mayer EL, Vaz-Luis I, Richardson AL, Perou CM, Tung NM, Abramson VG, Anders CK, Forero-Torres A, Marcom PK, Miller K, Puhalla S, Rimawi MF, Stearns V, Traina TA, Barry WT, Jones JT, Timms K, Hartman A-R, Wolff AC, Winer EP. TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. TPS1145–TPS1145.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2014

Volume

32

Issue

15_suppl

Start / End Page

TPS1145 / TPS1145

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences